Author

Mebarki B

Associate Professor, University of Maryland College Park - Cited by 6,752 - Targeting and Subcellular Transport of Drug Delivery Systems

Biography

Dr. Mebarki B is currently working at ENERGARID Laboratory, University of Bechar, Algeria . His research interest includes Thermal comfort, Energy storage, Electric vehicle. He is serving as an honorary reviewer for Advances in Automobile Engineering. He has authored of several research articles/books related to Thermal comfort, Energy storage, Electric vehicle.
Title
Cited by
Year
Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives
M Solomon, S MuroAdvanced drug delivery reviews 118, 109-134, 2017201
130
2017
Chitosan–Alginate Microcapsules Provide Gastric Protection and Intestinal Release of ICAM‐1‐Targeting Nanocarriers, Enabling GI Targeting In Vivo
R Ghaffarian, E Pérez‐Herrero, H Oh, SR Raghavan, S MuroAdvanced functional materials 26 (20), 3382-3393, 2016201
98
2016
A comparative study on the alterations of endocytic pathways in multiple lysosomal storage disorders
J Rappaport, RL Manthe, M Solomon, C Garnacho, S MuroMolecular pharmaceutics 13 (2), 357-368, 2016201
48
2016
Targeting superoxide dismutase to endothelial caveolae profoundly alleviates inflammation caused by endotoxin
VV Shuvaev, RY Kiseleva, E Arguiri, CH Villa, S Muro, ...Journal of Controlled Release 272, 1-8, 2018201
45
2018
Biodegradable “smart” polyphosphazenes with intrinsic multifunctionality as intracellular protein delivery vehicles
AP Martinez, B Qamar, TR Fuerst, S Muro, AK AndrianovBiomacromolecules 18 (6), 2000-2011, 2017201
39
2017
Size and targeting to PECAM vs ICAM control endothelial delivery, internalization and protective effect of multimolecular SOD conjugates
VV Shuvaev, S Muro, E Arguiri, M Khoshnejad, S Tliba, ...Journal of Controlled Release 234, 115-123, 2016201
38
2016
Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain
OA Marcos-Contreras, JS Brenner, RY Kiseleva, V Zuluaga-Ramirez, ...Journal of Controlled Release 301, 54-61, 2019201
35
2019
Enhanced delivery and effects of acid sphingomyelinase by ICAM-1-targeted nanocarriers in type B Niemann-Pick disease mice
C Garnacho, R Dhami, M Solomon, EH Schuchman, S MuroMolecular Therapy 25 (7), 1686-1696, 2017201
30
2017
Induced pluripotent stem cells for disease modeling and evaluation of therapeutics for Niemann-Pick disease type A
Y Long, M Xu, R Li, S Dai, J Beers, G Chen, F Soheilian, U Baxa, M Wang, ...Stem Cells Translational Medicine 5 (12), 1644-1655, 2016201
29
2016
Targeted carriers for intracellular drug delivery
S Muro-Galindo, VR MuzykantovUS Patent 9,707,9, 2017201
29
2017
Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance
J Kim, S Sinha, M Solomon, E Perez-Herrero, J Hsu, Z Tsinas, S MuroBiomaterials 147, 14-25, 2017201
26
2017
Alterations in cellular processes involving vesicular trafficking and implications in drug delivery
S MuroBiomimetics 3 (3), 19, 2018201
26
2018
How carrier size and valency modulate receptor-mediated signaling: understanding the link between binding and endocytosis of ICAM-1-targeted carriers
D Serrano, RL Manthe, E Paul, R Chadha, S MuroBiomacromolecules 17 (10), 3127-3137, 2016201
22
2016
ICAM‐1‐targeted nanocarriers attenuate endothelial release of soluble ICAM‐1, an inflammatory regulator
RL Manthe, S MuroBioengineering & translational medicine 2 (1), 109-119, 2017201
22
2017
Unprecedently high targeting specificity toward lung ICAM-1 using 3DNA nanocarriers
N Roki, Z Tsinas, M Solomon, J Bowers, RC Getts, S MuroJournal of Controlled Release 305, 41-49, 2019201
17
2019
Intertwined mechanisms define transport of anti-ICAM nanocarriers across the endothelium and brain delivery of a therapeutic enzyme
RL Manthe, M Loeck, T Bhowmick, M Solomon, S MuroJournal of Controlled Release 324, 181-193, 2020202
16
2020
Targeted protein replacement for the treatment of lysosomal storage disorders
SM Galindo, VR Muzykantov, EH SchuchmanUS Patent 9,655,953, 2017201
14
2017
DNA-based drug carriers: the paradox of a classical “cargo” material becoming a versatile “carrier” to overcome barriers in drug delivery
R Getts, S MuroCurrent pharmaceutical design 22 (9), 45-58, 2016201
12
2016
ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement
C Garnacho, S MuroJournal of drug targeting 25 (9-10), 786-795, 2017201
11
2017
Drug delivery across physiological barriers
S MuroCRC Press, 2016201
10
2016

Referred From: https://scholar.google.com/citations?user=--DTkMoAAAAJ&hl=en

Cited by
Citations 6752
h-index 45
i10-index 85
Recommended Journals
Open Access Journals